ARIAD Pharmaceuticals

ARIAD Pharmaceuticals, Inc. is a global oncology company focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.

ARIAD Pharmaceuticals was acquired by Takeda Pharmaceutical on January 9, 2017

Type
Subsidiary
Parent Company
Takeda Pharmaceutical
HQ
Cambridge, US
Founded
1991
Website
ariad.com
ARIAD Pharmaceuticals was founded in 1991 and is headquartered in Cambridge, US

ARIAD Pharmaceuticals Office Locations

ARIAD Pharmaceuticals has offices in Cambridge, Minneapolis, Boston, San Antonio and in 9 other locations
Cambridge, US (HQ)
26 Landsdowne St
Show all (13)

ARIAD Pharmaceuticals Financials and Metrics

ARIAD Pharmaceuticals Summary

Founding Date

1991
ARIAD Pharmaceuticals is a subsidiary of Takeda Pharmaceutical

ARIAD Pharmaceuticals Financials

ARIAD Pharmaceuticals's revenue was reported to be $118.8 m in FY, 2015
USDFY, 2013FY, 2014FY, 2015

Revenue

45.6 m105.4 m118.8 m

Revenue growth, %

131%13%

EBIT

(273.6 m)(160.2 m)(217.3 m)

EBIT margin, %

(600%)(152%)(183%)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Revenue

16.7 m11.8 m12.1 m14.7 m24 m29.2 m29.1 m35.6 m68.1 m46 m

Operating expense total

83 m61.4 m68.4 m61.8 m73.7 m87.8 m85.4 m83.5 m79.8 m71 m

EBIT

(66.2 m)(49.7 m)(56.3 m)(47.1 m)(49.7 m)(58.6 m)(56.4 m)(47.9 m)(11.7 m)(25 m)

EBIT margin, %

(396%)(421%)(465%)(321%)(207%)(200%)(194%)(134%)(17%)(54%)
USDFY, 2013FY, 2014FY, 2015

Cash

237.2 m352.7 m230.9 m

Accounts Receivable

1.3 m8.4 m15.7 m

Inventories

419 k

Current Assets

244.9 m385.6 m275.2 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Cash

284.4 m183 m310 m273.5 m304 m274 m282.2 m160.9 m273 m305 m

Accounts Receivable

7 m4.2 m5 m7.3 m11.3 m14.4 m15.5 m21.6 m14.1 m24 m

Inventories

577 k480 k925 k969 k704 k1.3 m1.5 m936 k903 k2.1 m

Current Assets

313.4 m199 m324.2 m289.4 m340.9 m301.1 m329.5 m209.2 m307.1 m351.2 m
USDFY, 2013FY, 2014FY, 2015

Net Income

(274.2 m)(162.6 m)(231.2 m)

Accounts Receivable

(1.3 m)(7.1 m)(7.3 m)

Inventories

(413 k)(560 k)1.1 m

Accounts Payable

2.5 m(137 k)5.5 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Net Income

(66.3 m)(49.8 m)(56.9 m)(50.1 m)(52.7 m)(53.8 m)56.1 m28.2 m

Accounts Receivable

(5.9 m)(7.4 m)(17.3 m)

Inventories

(92 k)(1.1 m)(2.3 m)

Accounts Payable

(4 m)(6.8 m)(5.8 m)
Show all financial metrics

ARIAD Pharmaceuticals Median Salaries

Source: 16 public H-1B filings from ARIAD Pharmaceuticals

ARIAD Pharmaceuticals's Web-traffic and Trends

ARIAD Pharmaceuticals Online and Social Media Presence

ARIAD Pharmaceuticals Company Life and Culture

You may also be interested in